Primary Efficacy Evaluation: 
Key Secondary Evaluation: 
Other Secondary Efficacy Evaluation: 
Safety Evaluation: 
Pharmacokinetic Evaluation: 
Sample Size: 
f
Primary Efficacy Analysis: 
Secondary and Exploratory Efficacy Analysis
Safety:
Pharmacokinetics/Pharmacodynamics (PK/PD):
Primary
Key Secondary 
Other Secondary
Safety
Pharmacokinetic
Run-In Visit (Visit 2) 
Baseline Sleep Laboratory Visits (Visit 3 – up to 10 days) 
Management of patients with OSA and CSA: 
Baseline/Randomization (Visit 4 – Day 0) 
Phone call/Liver Function Tests (Day 14, +/- 3 days) 
End of Study Sleep Laboratory Visits (Visit 5 on Day 28 – up to 10 days)
Final Study Clinic Visit (Visit 5 on Day 30, + 10 days) 
slept very well slept 
very badly
RBC Indices WBC Count with Differential 
f
Curr Neurol Neurosci Rep. 
Alzheimers Dement
J Clin Sleep Med
Biol Psychiatry
Acta Neurol Scand
. CNS Drugs
J Neural Transm (Vienna).
Brain
Lancet.
J Psychiatr Res
Expert Opin. 
Pharmacother
Lancet Neurol
Lancet Neurol
Swiss Med 
Wkly
J Am Geriatr Soc
et al
Mov Disord. 
Parkinson’s disease and non-motor function, Second edition
Biometrics
J Clin 
Psychiatry
in the past month 
at
night
during the day
too often
too long 
too early 
too little 